Physician profile
Zhenhui Li
NPI 1184694374
$2,861.02
in general payments reported to CMS, 2019-2025
16 companies · $842 in 2025
The $842 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.51 · 2020: $88.01 · 2021: $163 · 2022: $543 · 2023: $549 · 2024: $584 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,587 · Consulting Fee: $300 · Education: $87.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,586.86 |
| Consulting Fee | $300.00 |
| Education | $87.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,355.71 | 2021-2025 | |
| Biogen, INC. | $450.00 | 2021-2025 | Tysabri |
| Lundbeck LLC | $162.09 | 2022-2024 | Vyepti |
| Genentech USA, INC. | $125.90 | 2019-2025 | Ocrevus |
| Teva Pharmaceuticals USA, INC. | $124.17 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $115.72 | 2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $93.83 | 2022-2024 | |
| Lilly USA, LLC | $93.20 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Allergan, INC. | $88.01 | 2020 | |
| Ucb, INC. | $84.10 | 2022 | |
| Sk Life Science, INC. | $34.77 | 2025 | |
| Emd Serono, INC. | $33.66 | 2023 | Mavenclad |
| Pfizer INC. | $32.27 | 2025 | |
| Genzyme Corporation | $27.73 | 2025 | |
| Axsome Therapeutics, INC. | $23.56 | 2025 | Symbravo |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $16.30 | 2025 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zhenhui Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.